ESMO 2024: Optimising the personalisation of prostate cancer treatment
15 Sep 2024
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ERBB2 amplifications across sex, race, and cancer types studied to guide HER2 therapies
Psychological issues in familial cancer
Best practice in HRRm testing in patients with metastatic prostate cancer
Looking at real world evidence on PSA testing in prostate cancer
Stockholm3 offers a promising avenue for personalised risk-based prostate cancer diagnosis
The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer
iCCaRE Consortium for Black Men: Second Discussion